Follow-On Biologics Should Be Handled Through Legislation – Senate Staffer

The Senate Health Committee will evaluate the science and law of follow-on biologics, Health Policy Staff Director Northrup says. Although the committee's work is in the early stages, congressional action, not a "regulatory or administrative fiat" from FDA, is the next step.